

10/10/01

J1051 U.S. PTO

Please type a sign (+) inside this box + PTO/SB/05 (08-00)Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

PT056P1

First Inventor

SHI, Yanggu

Title

TM4SF Receptor Polynucleotides,
Polypeptides, And Antibodies

Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 202311. ☒ Fee Transmittal Form (e.g., PTO/SB/17) (in duplicate)
(Submit an original, and a duplicate for fee processing)2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.3. ☒ Specification [Total Pages 289]

(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]5. ☒ Unexecuted Declaration [Total Pages 2]

- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

i. ☐ **DELETION OF INVENTOR(S)**Signed statement attached deleting inventor(s) named in
the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).6. ☒ Application Data Sheet. See 37 CFR 1.76. (2 pages)7. ☐ CD-ROM or CD-R in duplicate, large table or Computer
Program (Appendix)8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☒ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper (4 pages)
- c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS9. ☐ Assignment Papers (cover sheet and document(s))10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney11. ☐ English Translation Document (if applicable)12. ☐ Information Disclosure Statement/ Form PTO/SB/08☐ Copies of Citations13. ☐ Preliminary Amendment14. ☒ Return Receipt Postcard (MPEP 503)
(should be specifically itemized)15. ☐ Certified copy of Priority Document(s)
(if foreign priority is claimed)16. ☐ Other:17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76:☒ See Application Data Sheet for priority information ☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No:
Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the
accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted
application parts.**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Label

22195

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

NAME (Print/Type) Kenley K. Hoover

Registration No. (Attorney/Agent) 40,302

SIGNATURE

Date October 10, 2001

Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete
should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

10/10/01
11059 U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2002

(Substitute form)

Patent fees are subject to annual revision.

Complete if Known

Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	SHI et al.
Examiner Name	Unassigned
Group Art Unit	Unassigned
Attorney Docket Number	PT056P1

Total amount of payment **776.00**

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

- ☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17
☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit Card ☐ Money Order ☐ Other*

FEE CALCULATION

BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		101	740	Utility filing fee	740.00
		106	330	Design filing fee	
		107	510	Plant filing fee	
		108	740	Reissue filing fee	
		114	160	Provisional filing fee	

SUBTOTAL (1) \$0.00

EXTRA CLAIM FEES

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
22	2		2	\$18.00	36.00
			0	\$84.00	0.00
				\$280.00	

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	203	18	9			Claims in excess of 20
102	202	84	42			Independent claims in excess of 3
104	204	280	140			Multiple dependent claim, if not paid
108	209	84	42			** Reissue independent claims over original patent
110	210	18	9			** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) \$ 36.00

* or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	205	130	65			Surcharge - late filing fee or oath	
127	227	50	25			Surcharge - late provisional filing fee or cover sheet	
139	139	130	130			Non-English specification	
142	242	1,280	640			Utility issue fee (or reissue)	
195	195	300	300			Publication fee for early, voluntary, or normal publication	
179	279	740	370			Request for Continued Examination (RCE)	
098	098	130	130			Processing fee, except in provisional applications	
126	126	180	180			Submission of Information Disclosure Statement	
123	123	50	50			Processing fee for provisional applications	
146	246	740	370			Filing a submission after final rejection (37 CFR 1.129(a))	
149	249	740	370			For each additional invention to be examined (37 CFR 1.129(b))	
145	145	100	100			Certificate of correction	
147	147	2,520	2,520			Request for <i>ex parte</i> reexamination	
099	099	8,800	8,800			Request for <i>inter partes</i> reexamination	
148	248	110	55			Statutory disclaimer	
115	215	110	55			Extension for reply within first month	
116	216	400	200			Extension for reply within second month	
117	217	920	460			Extension for reply within third month	
118	218	1,440	720			Extension for reply within fourth month	
128	228	1,960	980			Extension for reply within fifth month	
119	219	320	160			Notice of appeal	
120	220	320	160			Filing a brief in support of an appeal	
121	221	280	140			Request for oral hearing	
122	222	130	130			Petitions to the Commissioner	
140	240	110	55			Petition to revive unavoidably abandoned application	
141	241	1,280	640			Petition to revive unintentionally abandoned application	
091	091	1,280	1,280			Acceptance of an unintentionally delayed claim for priority	
561	561	3	3			Printed copy of patent, regular service	
581	481	40	40			Recording each patent assignment per property (times number of properties)	

Other fee (specify):

Other fee (specify):


Other fee (specify):

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) \$0.00

Submitted By

Complete (if applicable)

Name (Print/Type) Kerley K. Hoover	Registration No.: 40,302	Telephone 301-610-5771
Signature: 		Date: October 10, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SHI et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: TM4SF Receptor Polynucleotides,
Polypeptides, and Antibodies

Attorney Docket No.: PT056P1

STATEMENT UNDER 37 C.F.R. 1.821(f)


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Date: October 16, 2001


Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5771

KKH/JS/MJ/lcc